At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
Founded in March 2013 as a result of the technology and know-how accumulated over two decades at Children’s Hospital of Philadelphia (CHOP), our investigational therapies have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. Greater understanding of the human genome and genetic abnormalities have allowed our scientists to tailor investigational therapies to patients suffering from very specific genetic diseases. This approach holds great promise in developing effective treatments to a host of inherited diseases. Our initial focus is on treating orphan diseases.
Headquartered in dynamic Philadelphia, we are a diverse, experienced team united in our goal to break down barriers for people and families affected by genetic diseases. As our name suggests, our investigational, one-time therapies are designed to spark healthy biology, and deliver potentially life-altering transformation for people and families affected by genetic disease. Spark is a member of the Roche Group.
Challenge the inevitability of genetic disease by discovering, developing and delivering treatments in ways unimaginable – until now.
A world where no life is limited by genetic disease.
Dr. Federico Mingozzi is the chief scientific officer at Spark Therapeutics, bringing two decades of experience in gene therapy, immunology, as well as biochemistry and molecular biology in both industry and academic settings.
Federico began his scientific career studying the genetic basis of bleeding disorders. At the Children’s Hospital Philadelphia (CHOP) he conducted pioneering studies on liver gene transfer with adeno-associated virus (AAV) vectors and immunology. Federico was involved in several first-in-human clinical studies of gene therapy based on the AAV vector platform while serving as the director of translational research the Center for Cellular and Molecular Therapeutics, at CHOP. He also led studies aimed at the characterization of human immune responses to AAV vectors and the development of strategies to modulate vector immunogenicity.
He then joined the French National Institute of Health and Medical Research (INSERM) as Research Director and Genethon, a leading French nonprofit R&D organization focused on gene therapy for rare diseases, as Team Leader. There, he spearheaded the development of in vivo gene therapies for inherited diseases. His work continued to focus on the characterization of human immune responses to AAV vectors and on the development of strategies to overcome immune responses in gene transfer.
Throughout his distinguished career, Federico has received several awards and has contributed to the field of gene therapy with more than 100 scientific publications, including seminal findings in the field of AAV gene therapy. He is also the at-large director on the American Society of Gene and Cell Therapy (ASGCT) board of directors.
Federico received his bachelor’s degree in biology and his Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy, and his M.B.A. from Drexel University. Federico also served as faculty at the Pierre and Marie Curie University in Paris, France, and Universitat Autonoma de Barcelona, Spain.
Jeff Marrazzo founded and has led the growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now.
Under Jeff’s leadership, Spark received regulatory approval for the first gene therapy for a genetic disease approved in both the U.S. and EU, launched the first gene therapy for a genetic disease in the United States, and established human proof-of-concept of Spark’s gene therapy platform in both the retina and liver. In less than seven years, Jeff has built an organization of more than 450 colleagues while securing over $1 billion in capital and successfully orchestrating a merger with Roche. Spark has been named to the top 10 of Science Magazine’s 2019 Top Employer list, listed on the Philadelphia Business Journal’s Best Places to Work list three consecutive years and was awarded the Prix Galien for Best Biotechnology Product in 2019.
Prior to Spark, he helped build the first genetic testing benefit management up to and through the acquisition of a majority of the company’s shares by CVS Caremark. Previously, Jeff served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare.
Jeff currently serves as on the boards of the Life Science Cares Philadelphia and The Rendell Center for Civics and Civic Engagement. Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.
Jeff can be found on Twitter @JeffMarrazzo.
Lisa Dalton, who has more than 20 years of human resources experience across the biopharmaceutical and financial services industries, is responsible for four core functions — HR, IT, Corporate Facilities and Corporate Communications — focused on how to enable and empower Spark’s most important resource – its talented people. Lisa has been instrumental in helping lead the company’s growth from a few dozen people then to more than 500 people today. She began her tenure at Spark Therapeutics in July 2014 as the Head of Human Resources and joined the company’s corporate management team as Chief Human Resource Officer in 2018.
Lisa was previously vice president, human resources at Shire, where she led various human resources functions to meet the needs of a high-growth organization, including human resources-related merger and acquisition efforts, the total rewards function and the human resources operations function. While on international assignment in Switzerland, Lisa played a critical role in planning and launching Shire’s European hub, where she was a member of the site leadership team, championed the culture and values of the organization and had oversight of the talent strategies for the newly established site.
Lisa also has held roles in human resources with Franklin Templeton Investments, Applied Biosystems and Goldman Sachs.
Lisa serves as a member of the Board of Advisors of Life Science Cares Philadelphia. She holds an M.B.A. from Rutgers University School of Business and a B.A. in psychology from Pennsylvania State University.
Ron Philip leads all aspects of product strategy at Spark, including new product and commercial development activities for Spark’s early and late-stage pipeline assets. He is also responsible for all commercial operations including sales, marketing, diagnostics, market access and patient services functions for inline products. At Spark, he has successfully led the development and implementation of commercial strategy, novel distribution and reimbursement models for the first gene therapy approved for a genetic disease in the U.S.
Ron has more than 20 years of experience in the pharmaceutical industry with a proven track record of improving operating performance in multiple therapeutic categories and global markets. Prior to joining Spark Therapeutics, he served in several senior leadership roles at Pfizer including Regional President – Africa Middle East, Head of Global Business Unit Strategy, Head of Business Development Search & Evaluation and Commercial Development within Pfizer’s Innovative Products Business.
He previously worked at Wyeth Pharmaceuticals in U.S. commercial operations, with Deloitte Consulting in their strategy and operations practice and at Merck and Co. in the manufacturing and marketing divisions.
Ron is an alumnus of Drexel University.
Joe La Barge serves as the Chief Business Officer of Spark Therapeutics, Inc., where he oversees business development, government affairs, legal, compliance, patient advocacy and pricing and reimbursement. As of Dec. 2019, he is also leading the Finance function on an interim basis.
Joe served as the Chief Legal Officer from 2013 to 2020, during which time he led multiple public and private financings, raising more than $1 billion in capital, structured multiple collaborations and partnerships and negotiated the merger with the Roche Group, including successfully guiding Spark through antitrust reviews by the U.S. Federal Trade Commission and the U.K. Competition and Market Authority. He has been instrumental in the development of novel distribution and reimbursement models for one-time therapeutics.
Prior to joining Spark, Joe spent 20 years as a corporate attorney in private practice and in-house representing private and public companies in mergers and acquisitions (M&A), licensing transactions, corporate governance matters and capital raising transactions.
Joe currently serves on the Board of Director of the National Pharmaceutical Council. He received a B.A. from Bucknell University and a J.D. from Temple University – James E. Beasley School of Law in Philadelphia, where he served as Editor in Chief of the Temple Law Review.
Dr. Gallia Levy is the Chief Medical Officer at Spark Therapeutics and leads strategic and operational teams throughout the product development lifecycle with responsibility for setting the global development strategy for current and pipeline programs. She serves as the principal physician and resident medical expert at Spark.
Prior to joining Spark, Gallia was Vice President and Global Head of the Rare Blood Disorders Franchise in Product Development at Genentech, another member of the Roche Group, where she was responsible for the clinical development of treatments for hemophilia A and other rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome (aHUS). Gallia first joined Genentech in 2009, where she worked in both early and late-stage clinical development. She later moved to Portola Pharmaceuticals, where she led the clinical development program for hematology and oncology indications spanning Phases 1 to registrational trials. She eventually returned to Genentech, taking responsibility for the global clinical development program for HEMLIBRA® during which time she led the transition from Phase 1 through to global registration for adults and children with hemophilia A.
Gallia is board-certified in hematology and earned an M.D. and Ph.D. in Molecular and Cellular Biology from the University of Michigan, during which time discovered ADAMTS13, responsible for Thrombotic Thrombocytopenic Purpura (TTP). She completed her residency in internal medicine at Stanford University and a fellowship in hematology at the University of California, San Francisco. She also spent time at the Pasteur Institute during which she received an M.S. in Molecular and Cellular Biology from the University of Paris, VI and she holds a B.A. from the University of California, Berkeley.